Assessment of patients with psoriatic arthritis: A review of currently available measures

Gladman, Dafna D.; Helliwell, Philip S.; Mease, Philip J.; Nash, Peter; Ritchlin, Christopher T.; Taylor, William J.

doi:10.1002/art.11417

Cited by 170 publications

(128 citation statements)

References 46 publications

Supporting

Mentioning

123

Contrasting

Unclassified

Order By: Relevance

“…46,47 It is unclear whether the ACR 20 has the same discriminatory validity in PsA. 48 The ACR 20 is generally accepted to be the minimal clinically important difference that indicates some response to a particular intervention. The ACR 50 reflects significant and important changes in the patient's disease status that may be acceptable to both clinician and patient in long-term management.…”

Section: American College Of Rheumatology Response Criteriamentioning

confidence: 99%

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation

Rodgers

Epstein²,

Bojke³

et al. 2011

Health Technol Assess

100

155

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. ii ii HTA NIHR Health Technology Assessment programmeThe Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service' . The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of pro...

show abstract

Section: American College Of Rheumatology Response Criteriamentioning

confidence: 99%

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation

Rodgers

Epstein²,

Bojke³

et al. 2011

Health Technol Assess

100

155

View full text Add to dashboard Cite

show abstract

“…Outcome measures in PsA are not standardized and most of the assessment methodologies have been adapted from clinical trials in rheumatoid arthritis (RA), with few disease-specific instruments for PsA currently available (2). Recently, the Outcome Measures in Rheumatology (OMERACT) proposed a core set of 6 domains of health to be included in randomized clinical trials (RCTs) and observational studies regarding PsA: joints, skin, pain, patient global assessment, physical function, and health-related quality of life (3).…”

Section: Introductionmentioning

confidence: 99%

Clinical outcomes in psoriatic arthritis: A systematic literature review

Palominos¹,

Gaujoux-Viala²,

Fautrel³

et al. 2012

Arthritis Care & Research

View full text Add to dashboard Cite

Objective. Many outcomes have been proposed in the assessment of psoriatic arthritis (PsA). The Outcome Measures in Rheumatology (OMERACT) core set for PsA evaluation comprises 6 domains: joints, skin, function, pain, patient's global assessment, and quality of life. The objective of this work was to assess reporting of outcomes in PsA, including patient-reported outcomes (PROs) in recent publications. Methods. A systematic literature search of clinical trials related to PsA and reporting at least 1 clinical outcome between 2006 and 2010 was performed in PubMed, i.e., just before to just after publication of the OMERACT core set. All clinical outcomes were noted and subdivided into domains of health. Data analysis was descriptive. Results. Fifty-eight articles (12,405 patients) were included in the analysis: 17 (29%) were randomized clinical trials; the patients' mean ؎ SD age was 48.2 ؎ 5.4 years and the mean ؎ SD disease duration was 9.0 ؎ 3.1 years. Eighty-four different outcomes were reported, with a mean ؎ SD of 6.9 ؎ 4.3 per study. Patients were mainly assessed using the 6 core set domains, reported in 37.9% (quality of life) to 55.2% (skin) of articles; however, the core set was rarely completely reported since only 10.3% of the studies reported all 6 core domains. PROs were heterogeneous and in particular there was no consensus regarding the number of joints to assess and instruments for dactylitis and enthesitis. PROs were assessed in more than 75% of publications using 28 different instruments. Conclusion. There is great heterogeneity in PsA assessment, even since publication of the OMERACT core set. Better consensus on instruments to assess each domain of health and better insight into which outcomes are important for patients is needed.

show abstract

“…Comprehensive assessment of patients with psoriatic arthritis (PsA) involves evaluation of joints, dactylitis, skin, and nails (1)(2)(3)(4)(5). Nail lesions are very common and help distinguish between patients who have PsA and those who have rheumatoid arthritis (6).…”

Section: Introductionmentioning

confidence: 99%

Is the nail psoriasis severity index reliable in the assessment of nail psoriasis by rheumatologists?

Lubrano

Cantini

Marchesoni

et al. 2012

Arthritis Care & Research

View full text Add to dashboard Cite

show abstract

Assessment of patients with psoriatic arthritis: A review of currently available measures

Cited by 170 publications

References 46 publications

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation

Clinical outcomes in psoriatic arthritis: A systematic literature review

Is the nail psoriasis severity index reliable in the assessment of nail psoriasis by rheumatologists?

Contact Info

Product

Resources

About